Nicola Biagio Mercuri

Author PubWeight™ 22.54‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp Neurol 2008 1.71
2 Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons. Neuroreport 2002 0.98
3 Rapid constitutive and ligand-activated endocytic trafficking of P2X receptor. J Neurochem 2009 0.97
4 Oxidative stress in stroke pathophysiology validation of hydrogen peroxide metabolism as a pharmacological target to afford neuroprotection. Int Rev Neurobiol 2009 0.95
5 Therapeutic potential of targeting hydrogen peroxide metabolism in the treatment of brain ischaemia. Br J Pharmacol 2012 0.91
6 Identification of distinct cellular pools of interleukin-1beta during the evolution of the neuroinflammatory response induced by transient middle cerebral artery occlusion in the brain of rat. Brain Res 2009 0.89
7 Effects of zonisamide as add-on therapy on sleep-wake cycle in focal epilepsy: a polysomnographic study. Epilepsy Behav 2013 0.88
8 Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009 0.87
9 Age-related changes of hippocampal synaptic plasticity in AβPP-null mice are restored by NGF through p75NTR. J Alzheimers Dis 2013 0.86
10 Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Brain 2009 0.86
11 Electrophysiological effects of trace amines on mesencephalic dopaminergic neurons. Front Syst Neurosci 2011 0.84
12 N-Glycans mutations rule oligomeric assembly and functional expression of P2X3 receptor for extracellular ATP. Glycobiology 2010 0.81
13 A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation. PLoS One 2012 0.81
14 Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions. Neuropharmacology 2013 0.81
15 Cocaine dependence and stroke: pathogenesis and management. Curr Neurovasc Res 2015 0.80
16 Synaptic plasticity in the basal ganglia: a similar code for physiological and pathological conditions. Prog Neurobiol 2007 0.80
17 CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis? J Sleep Res 2014 0.80
18 (-)-Linalool attenuates allodynia in neuropathic pain induced by spinal nerve ligation in c57/bl6 mice. Int Rev Neurobiol 2009 0.79
19 Resistance to striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice expressing human mutant Cu,Zn superoxide dismutase. Neurosci Lett 2002 0.78
20 The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells. Br J Pharmacol 2009 0.78
21 The protective role of catalase against cerebral ischemia in vitro and in vivo. Int J Immunopathol Pharmacol 2011 0.78
22 Sleep disorders in spinal and bulbar muscular atrophy (Kennedy's disease): a controlled polysomnographic and self-reported questionnaires study. J Neurol 2014 0.77
23 A continuous high frequency stimulation of the subthalamic nucleus determines a suppression of excitatory synaptic transmission in nigral dopaminergic neurons recorded in vitro. Exp Neurol 2011 0.77
24 Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration. Neurotox Res 2010 0.77
25 Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure. Clin Drug Investig 2014 0.77
26 Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. CNS Neurol Disord Drug Targets 2016 0.76
27 Electroencephalography and dementia: a literature review and future perspectives. CNS Neurol Disord Drug Targets 2013 0.76
28 The midbrain slice preparation. An in vitro model to select potential anti-parkinsonian drugs? Parkinsonism Relat Disord 2008 0.75
29 Intermittent short sleep may contribute to orexinergic signaling dysregulation in Alzheimer's Disease. Sleep 2016 0.75